Revelation Biosciences Stock Today
| REVBW Stock | USD 0.02 0.0009 4.81% |
PerformanceOK
| Odds Of DistressHigh
|
Revelation Biosciences is selling for under 0.0178 as of the 16th of February 2025; that is 4.81 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0151. Revelation Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2020 | Category Healthcare | Classification Health Care |
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company was founded in 2019 and is based in New York, New York. More on Revelation Biosciences
Moving against Revelation Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Revelation Stock Highlights
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Health Management, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Revelation Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Revelation Biosciences' financial leverage. It provides some insight into what part of Revelation Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Revelation Biosciences (REVBW) is traded on NASDAQ Exchange in USA. It is located in 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 and employs 9 people. Revelation Biosciences is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Revelation Biosciences has accumulated about 4.14 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Revelation Biosciences Probability Of Bankruptcy
Revelation Biosciences Historical Income Statement
Revelation Stock Against Markets
Revelation Biosciences Corporate Management
| James Rolke | CEO Director | Profile | |
| Carol Odle | Director Projects | Profile | |
| Chester III | Chief Officer | Profile | |
| Sandra Vedrick | Vice Relations | Profile |
Additional Tools for Revelation Stock Analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.